Seeking Alpha

With Orexigen's (OREX -72%) bad news, the near-term pipeline for obesity drugs is rather...

With Orexigen's (OREX -72%bad news, the near-term pipeline for obesity drugs is rather thin: Novo Nordisk (NVO +1.5%) and Amylin (AMLN +0.7%) look to be the next candidates to offer a new FDA-approved option for the disease, while companies like Isis Pharmaceuticals (ISIS +1.8%) and its antisense-based candidate are likely at least 10 years from market approval.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs